<DOC>
	<DOCNO>NCT02834390</DOCNO>
	<brief_summary>This phase 1b , dose escalation , study quizartinib evaluate safety profile , pharmacokinetics , recommend dose quizartinib subsequent clinical study combination quizartinib induction consolidation chemotherapy .</brief_summary>
	<brief_title>Study Quizartinib Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>No prior treatment AML ( include quizartinib ) ECOG ( Eastern Cooperative Oncology Group ) Performance Status 0 2 Diagnosis acute promyelocytic leukemia Active acute chronic systemic fungal , bacterial , viral infection well controlled antifungal , antibacterial antiviral therapy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>phase 1</keyword>
	<keyword>hematology</keyword>
	<keyword>malignancy</keyword>
	<keyword>newly diagnose</keyword>
</DOC>